van der Vies J
Acta Endocrinol Suppl (Copenh). 1977;214:90-102.
Because of Dr. G. A. Overbeek's interest and contributions in the field of oral contraception a survey is given of present leads and developments in this area. It is concluded that contraceptive preparations known under names such as: once-a-month pill, morning-after pill and post-coitum pill, although desired, do not really exist at the moment. It is further expected that oral contraception based on the inhibition of ovulation will stay with us for many years to come. Better preparations, not exclusively containing oestrogen progestagen combinations but possibly including a non-hormonal pituitary inhibitor as well, might be developed. This will allow better control over the endometrium, and the unwanted effects of the presently used hormonal substances. It is likely that an implantation-inhibiting compound or an abortifacient which acts shortly after implantation will be found. With respect to oral contraception for males it is concluded that, although inhibition of spermatogenesis with drugs is possible, a satisfactory contraceptive treatment for men is not yet available.
鉴于G. A. 奥弗贝克博士在口服避孕领域的兴趣和贡献，现对该领域当前的线索和进展进行综述。得出的结论是，诸如每月服用一次的避孕药、事后避孕药和性交后避孕药等虽为人所期望，但目前实际上并不存在。进一步预计，基于抑制排卵的口服避孕方法在未来许多年内仍将存在。可能会研发出更好的制剂，这些制剂不仅含有雌激素 - 孕激素组合，还可能包括一种非激素性垂体抑制剂。这将能够更好地控制子宫内膜以及目前所用激素物质的不良影响。有可能会找到一种抑制着床的化合物或一种在着床后不久起作用的堕胎药。关于男性口服避孕，得出的结论是，虽然用药物抑制精子发生是可能的，但目前还没有令人满意的男性避孕治疗方法。
